Compare IDEXX Laboratories, Inc. (IDXX) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Trade Desk Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Trade Desk Inc trades at $12.11 (market cap $5.83B). The key difference: IDEXX Laboratories, Inc. is far larger — about 6.9× Trade Desk Inc's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 15,864,392). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Trade Desk Inc for 72 Days on average.
| IDXX | TTD | |
|---|---|---|
Market Cap | $40.43B | $5.83B |
Volume | 692,164 | 15,864,392 |
Sector | Health | Media |
52-Week High | $766.68 | $54.13 |
52-Week Low | $504.70 | $11.92 |
Typical Hold Time | 46 Days | 72 Days |
Enterprise Value | $41.32B | $4.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
The Trade Desk (TTD) trades at $12.08, down 0.08% with a bearish technical signal. The company shows strong fundamentals with 2025 revenue of $2.90B and net income of $443.30M, though 2026 guidance indicates slowing growth. Valuation metrics appear attractive with P/E of 0.15 and P/S of 0.02. Recent news highlights competitive pressures from Amazon and Alphabet while the company navigates workforce reductions.
Investment outlook remains cautious despite attractive valuations. The stock faces headwinds from slowing revenue growth and intense competition, but maintains leadership in programmatic advertising. Analyst consensus suggests 22% upside to $14.72 target, though mixed ratings reflect uncertainty about near-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
